文章：

前列腺癌患者当前治疗强化策略综述

Review of Current Treatment Intensification Strategies for Prostate Cancer Patients

原文发布日期：28 November 2023

DOI: 10.3390/cancers15235615

类型: Article

开放获取: 是

英文摘要：

Prostate cancer (PCa) used to be one of the most common nondermatologic cancers in men that can be treated only with surgery. However, a revolutionary breakthrough came in the 1980s with the introduction of long-acting luteinizing hormone-releasing hormone (LHRH) agonists for the curative treatment of PCa. This paradigm shift contributed to the combined use of androgen deprivation therapy (ADT), chemotherapy, and radiotherapy for the treatment. The latest data highlight the use of treatment intensification (TI), i.e., combined use of radiotherapy (RT) and hormonal or drug treatments, for localized or locally advanced PCa. Indeed, the results of combined modality treatments have shown a reduction in disease-specific mortality and improved overall survival. Although TI seems promising, more research studies are warranted to confirm its efficacy. This review summarizes the latest available outcome results of pivotal trials and clinical studies on the efficacy of TI.

摘要翻译： 

前列腺癌（PCa）曾是男性中最常见的非皮肤性恶性肿瘤之一，过去仅能通过手术治疗。然而，20世纪80年代长效促黄体激素释放激素（LHRH）激动剂的引入，为前列腺癌的根治性治疗带来了革命性突破。这一治疗范式的转变推动了雄激素剥夺疗法（ADT）、化疗与放疗的联合应用。最新研究数据强调，针对局限性或局部晚期前列腺癌，可采用治疗强化（TI）策略，即放疗（RT）与激素或药物治疗的联合方案。事实上，联合治疗模式已显示出降低疾病特异性死亡率并改善患者总生存期的效果。尽管治疗强化策略前景广阔，仍需更多研究验证其疗效。本综述总结了当前关于治疗强化疗效的关键试验与临床研究的最新结果。

原文链接：

Review of Current Treatment Intensification Strategies for Prostate Cancer Patients